Boulevard Bio
Boulevard Bio Launches With Approximately $65M From Deerfield for Precision Immunology
Boulevard Bio announced $65M in Equity and Convertible Notes financing on August 12, 2026. Boulevard Bio announced its emergence from stealth with approximately $65 million in aggregate financing from Deerfield and affiliates, provided in equity capital and convertible notes.
Round details
The financing includes backing from Deerfield Management. The company did not publish a valuation with the announcement.
- Round: Equity and Convertible Notes
- Capital announced: $65M
- Headquarters: New York, NY
How the company plans to use the capital
The announcement did not specify a detailed use of proceeds. The release said the company is advancing a broad pipeline of multi-specific antibodies for B cell-driven autoimmune diseases, including BLVD101 in Phase 1 and BLVD201 in IND-enabling studies.
Why this matters for GTM teams
The launch shows an immunology company emerging from stealth with early clinical data on a bispecific antibody, aimed at B cell-driven autoimmune diseases.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Boulevard Bio launch and financing announcement.
Company Info
Investors (1)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started